PTPN23

Across TCGA pan-cancer cohorts, PTPN23 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTPN23 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PTPN23 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTPN23 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

GBM, COAD, and PDAC are the cancer types where PTPN23 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.556	0.785	.015	7	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
PDAC	DFS	Tertile	III,IV	0.822	0.357	.013	5	view →
CCRCC	OS	Quartile	All	0.913	0.705	.012	4	view →
LSCC	OS	Median	III,IV	0.549	0.905	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTPN23–GBM (DFS)

Open the GBM breakdown →